Madrigal Pharm up 260% from US$69 to $230 on 26vs10% result NASH results in the MAESTRO-NASH trial showed that patients on resmetirom 80 mg and 100 mg after 52 weeks of treatment had, respectively, NASH resolution of 26% and 30% compared to 10% for placebo.
For liver fibrosis, a ≥1-stage improvement in fibrosis with no worsening of NAFLD Activity Score (NAS) was seen in, respectively, 24% and 26% of resmetirom 80 mg and 100 mg patients and 14% of placebo patients.
https://www.google.com/search?q=madrigal+pharmaceuticals+stock&oq=madrga&aqs=chrome.3.69i57j46i10i131i199i433i465i512j0i10i131i433i512l3j0i10i512j46i10i512j0i3i10j46i10i512.8545j0j7&sourceid=chrome&ie=UTF-8